breast-cancer-2017-scientifictracks-abstracts

3 / 26

Page 35
Notes:
conferenceseries.com
Volume 2, Issue 3 (Suppl) Breast Can Curr Res, an open access journal
ISSN: 2572-4118 Breast Cancer 2017
June 15-17, 2017
June 15-17, 2017 London, UK
5th World Congress on
Breast Cancer
FOXK2 aberration in breast cancers
Amy Hong Zhang
University of Texas, USA
The chromosome 17 is a frequent site of cancer-associated genetic anomalies and is strongly associated with poor prognosis.
Previous studies of breast cancer have revealed the amplification of several genomic regions on 17q. These amplifications
are typically discontinuous and complex in structure, suggesting that multiple oncogenes in this chromosomal segment may be
co-selected during breast carcinogenesis. By integrative analysis of public genomic datasets of breast cancers from the cancer
genome atlas (TCGA) including 910 tumor cases and 981 normal controls, we have found that FOXK2 in 17q25 displayed
frequent genomic amplifications and correlated gene expression changes in all subtypes of breast cancers classified by PAM50
compared to normal controls. Its overexpression was associated with poor overall survival of breast cancer patients. FOXK2
knockdown using lentivirus mediated shRNAs inhibited breast cancer cell proliferation and anchorage-independent growth in
four breast cancer cell lines with high FOXK2 expression status (MDA-MB-231, MCF-7, HCC1954 and MDA-MB-361). More
importantly, overexpression of FOXK2 and oncogene RAS induced MCF10A cell colony formation, indicating that FOXK2 is
an oncogene in breast cancer. The potential interacting molecules/pathways were explored using RNASeq technique on the
FOXK2 knockdown breast cancer cells. Several pathways, including regulation of cell proliferation, regulation of cell division,
cell adhesion and regulation of cell metabolism, were regulated by FOXK2 in breast cancer cells. Our data provide compelling
evidence that FOXK2 is an oncogene in breast tumorigenesis, and it might be a novel therapeutic target and a biomarker
predicting poor outcome The chromosome 17 is a frequent site of cancer-associated genetic anomalies and is strongly
associated with poor prognosis. Previous studies of breast cancer have revealed the amplification of several genomic regions
on 17q. These amplifications are typically discontinuous and complex in structure, suggesting that multiple oncogenes in this
chromosomal segment may be co-selected during breast carcinogenesis. By integrative analysis of public genomic datasets of
breast cancers from the cancer genome atlas (TCGA) including 910 tumor cases and 981 normal controls, we have found that
FOXK2 in 17q25 displayed frequent genomic amplifications and correlated gene expression changes in all subtypes of breast
cancers classified by PAM50 compared to normal controls. Its overexpression was associated with poor overall survival of
breast cancer patients. FOXK2 knockdown using lentivirus mediated shRNAs inhibited breast cancer cell proliferation and
anchorage-independent growth in four breast cancer cell lines with high FOXK2 expression status (MDA-MB-231, MCF-
7, HCC1954 and MDA-MB-361). More importantly, overexpression of FOXK2 and oncogene RAS induced MCF10A cell
colony formation, indicating that FOXK2 is an oncogene in breast cancer. The potential interacting molecules/pathways were
explored using RNASeq technique on the FOXK2 knockdown breast cancer cells. Several pathways, including regulation of cell
proliferation, regulation of cell division, cell adhesion and regulation of cell metabolism, were regulated by FOXK2 in breast
cancer cells. Our data provide compelling evidence that FOXK2 is an oncogene in breast tumorigenesis, and it might be a novel
therapeutic target and a biomarker predicting poor outcome.
Biography
Amy Hong Zhang is an Associate Professor in the Department of Pathology and Translational Molecular Pathology in University of Texas-MD, Anderson Cancer
Center in Houston, TX she is an American Board certified practicing Pathologist since 2003. She has expertise in diagnosing breast cancers and the interpretation
of the biomarkers relevant to breast cancers for patient care. She is also actively supervising research scientists and trainees on translational and laboratory
research, focusing on the characterization of tumor markers significant for breast tumorigenesis and the development of small molecule inhibitors and potential
novel molecular targets for breast cancer treatment.
Amy Hong Zhang, Breast Can Curr Res 2017, 2:3(Suppl)
DOI: 10.4172/2572-4118-C1-005